Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glibenclamide induced prolonged hypoglycaemia.

M Sonnenblick, S Shilo

    Age and Ageing
    |May 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Glibenclamide can cause prolonged hypoglycemia, especially in elderly patients with kidney or heart issues. Careful use is advised for these vulnerable populations to prevent severe low blood sugar events.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Calculated versus measured pure tone bone conduction 3 kHz thresholds in sudden sensorineural hearing loss.

    The Journal of laryngology and otology·2021
    Same author

    Risk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality: a case-control study.

    Infection·2012
    Same author

    Hyponatraemia in older people as a sign of adrenal insufficiency: a case-control study.

    Internal medicine journal·2010
    Same author

    Severe hyponatraemia in elderly hospitalized patients: prevalence, aetiology and outcome.

    Internal medicine journal·2010
    Same author

    Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease.

    Clinical and experimental rheumatology·2008
    Same author

    The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations.

    Clinical and experimental rheumatology·2007
    Same journal

    Overlapping premorbid frailty, multimorbidity and malnutrition and their associations with poor outcomes in patients with stroke.

    Age and ageing·2026
    Same journal

    Overall and cause-specific mortality and associated risk factors among middle-aged and older South Africans: findings from the health and ageing in Africa: a longitudinal study of an INDEPTH community in rural South Africa (HAALSI).

    Age and ageing·2026
    Same journal

    Effect of antihypertensive medication reduction on short-term blood pressure control in older adults: calibration of OPTiMISE trial results to real-world primary care data.

    Age and ageing·2026
    Same journal

    New horizons in advance care planning: narratives, identity and cultural humility.

    Age and ageing·2026
    Same journal

    Correction to: How a geriatrician-led emergency department model works in practice: a realist evaluation.

    Age and ageing·2026
    Same journal

    Effects of a home-based exercise and physical activity intervention after inpatient rehabilitation on real-world mobility in older adults with cognitive impairment: a secondary analysis of a randomised controlled trial.

    Age and ageing·2026
    See all related articles

    Area of Science:

    • Geriatric Medicine
    • Clinical Pharmacology
    • Endocrinology

    Background:

    • Glibenclamide is a sulfonylurea medication used to treat type 2 diabetes.
    • Hypoglycemia, or low blood sugar, is a known side effect of sulfonylureas.
    • Prolonged hypoglycemia can lead to serious complications.

    Purpose of the Study:

    • To investigate the incidence and characteristics of prolonged hypoglycemia associated with glibenclamide treatment.
    • To identify risk factors predisposing patients to severe hypoglycemia from glibenclamide.

    Main Methods:

    • Retrospective analysis of 13 hospitalized patients experiencing prolonged hypoglycemia.
    • Review of glibenclamide dosage, duration of hypoglycemia, and patient comorbidities.

    Related Experiment Videos

    Main Results:

    • 13 patients developed prolonged hypoglycemia (serum glucose ≤ 50 mg/dl for > 12 hours) despite glucose treatment.
    • Mean glibenclamide dose was 6.7 mg/day; hypoglycemia occurred within 7 days in 9 patients.
    • Elderly patients (≥ 68 years) with renal failure or congestive heart disease were particularly susceptible.

    Conclusions:

    • Glibenclamide can induce severe and prolonged hypoglycemia, especially in the elderly.
    • Renal and cardiac insufficiency are significant contributing factors to glibenclamide-induced hypoglycemia.
    • Caution is strongly recommended when prescribing glibenclamide to elderly patients and those with renal or cardiac compromise.